etodolac has been researched along with nabumetone in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Anderluh, M; Brunskole, M; Gobec, S; Lanisnik Rizner, T; Stefane, B; Stojan, J; Zorko, K | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Blower, PR; Gentry, C; Melarange, R; Spangler, R; Toseland, CD | 1 |
| Blower, PR; Durie, M; Gentry, C; Melarange, R; O'Connell, C | 1 |
| Amadio, P; Cummings, DM | 1 |
| Spangler, RS | 1 |
| Lanza, FL | 1 |
| Constantine, G; Schnitzer, TJ | 1 |
| Bensen, W; Zizzo, A | 1 |
| Rothstein, R | 1 |
| de Nucci, G; Ferraz, JG; Giuliano, F; Pereira, R; Warner, TD | 1 |
| Browning, RA; Burgess, FW | 1 |
| Harmon, FA; Snyder, JR; Van Hoogmoed, LM | 1 |
6 review(s) available for etodolac and nabumetone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; Drug Costs; Etodolac; Gastrointestinal Diseases; Humans; Incidence; Ketorolac; Nabumetone; Osteoarthritis; Oxaprozin; Propionates; Tolmetin | 1994 |
Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose-Response Relationship, Drug; Etodolac; Gastric Mucosa; Gastrointestinal Diseases; Intestinal Mucosa; Nabumetone; Prostaglandins; Rats | 1993 |
Gastrointestinal toxicity of newer NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; Nabumetone; Oxaprozin; Peptic Ulcer; Propionates; Risk Factors | 1993 |
Newer, safer nonsteroidal anti-inflammatory drugs. Rational NSAID selection for arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Butanones; Drug Therapy, Combination; Etodolac; Humans; Misoprostol; Nabumetone | 1998 |
Safety profiles of leading nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Consumer Product Safety; Etodolac; Humans; Nabumetone; Oxaprozin; Product Surveillance, Postmarketing; Propionates; United States | 1998 |
2 trial(s) available for etodolac and nabumetone
| Article | Year |
|---|---|
Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Method; Etodolac; Female; Humans; Male; Middle Aged; Nabumetone; Naproxen; Osteoarthritis; Pain Measurement; Placebos | 1997 |
Cyclooxygenase selectivity of non-steroid anti-inflammatory drugs in humans: ex vivo evaluation.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Etodolac; Humans; Isoenzymes; Male; Meloxicam; Membrane Proteins; Nabumetone; Naproxen; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Sulfonamides; Thiazines; Thiazoles; Time Factors; Tumor Cells, Cultured | 2001 |
9 other study(ies) available for etodolac and nabumetone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
Topics: Amino Acid Sequence; Ascomycota; Benzopyrans; Enzyme Inhibitors; Fungal Proteins; Melanins; Models, Molecular; Molecular Sequence Data; Oxidoreductases Acting on CH-CH Group Donors; Recombinant Proteins; Structural Homology, Protein; Substrate Specificity | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Butanones; Carrageenan; Cecum; Digestive System; Etodolac; Exudates and Transudates; Gastrointestinal Hemorrhage; Haptoglobins; Hemoglobins; Ileum; Male; Nabumetone; Propionates; Prostaglandins; Rats; Rats, Wistar; Time Factors; Ulcer | 1994 |
Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cecum; Depression, Chemical; Dinoprostone; Edema; Etodolac; Gastric Mucosa; Gastrointestinal Hemorrhage; Haptoglobins; Hemoglobins; Intestinal Mucosa; Male; Nabumetone; Rats; Rats, Wistar | 1994 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
In vitro investigation of the effects of cyclooxygenase-2 inhibitors on contractile activity of the equine dorsal and ventral colon.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Colon; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Horses; In Vitro Techniques; Indomethacin; Isoenzymes; Muscle Contraction; Muscle, Smooth; Nabumetone; Prostaglandin-Endoperoxide Synthases | 2002 |